Attyloid

Phase 1

Düsseldorf, GermanyFounded 2018attyloid.com

Founded in 2018 as an academic spin-off from Forschungszentrum Jülich, Attyloid is dedicated to advancing the molecular understanding of protein misfolding diseases. Its core sFIDA technology enables the detection of biomarkers at unprecedented sensitivity across various biological matrices, including blood, CSF, and even stool. The company's work is pivotal for CNS biomarker development, drug efficacy testing, and has been featured in high-profile clinical trials and peer-reviewed publications.

Founded

2018

Focus

Diagnostics

AI Company Overview

Technology Platform

sFIDA (Surface-based Fluorescence Distribution Analysis): An ultra-sensitive platform combining immunoassay specificity with fluorescence microscopy to quantitatively detect and count single protein oligomers and aggregates, serving as biomarkers for CNS and other diseases.

Opportunities

Significant opportunities exist in partnering with large pharma companies for clinical trial biomarker analysis and patient stratification.

The growing demand for blood-based, early diagnostic tests for Alzheimer's and Parkinson's represents a multi-billion dollar market where sFIDA's sensitivity could be a key differentiator.

Risk Factors

Key risks include the challenge of commercializing a novel platform technology against established competitors, dependence on the continued validation of the oligomer hypothesis in neurodegenerative diseases, and securing sufficient funding as a private company to achieve scale and regulatory milestones.

Competitive Landscape

Attyloid competes with ultra-sensitive diagnostic platforms like Quanterix's SIMOA and emerging blood-based Alzheimer's tests (e.g., from Lilly, C2N). Its differentiation lies in directly quantifying the specific toxic oligomeric species, rather than total protein or phospho-isoforms, and its single-particle counting capability for diverse applications beyond neurology.